Transforming growth factor-β signaling helps specify tumor type in DMBA and hormone-induced mammary cancers

Differentiation

Volumn 74, Issue 1, 2006, Pages 40-52

  Crowley, Michael R ^a,d   Frost, Andra ^b   Chen, Dung Tsa ^c   Baffi, Michael O ^a   Nicola, Teodora ^a   Serra, Rosa ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

DMBA; Hormone induced; Mammary cancer; Myoepithelial cells; Squamous cells; TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; CYTOKERATIN 14; DIMETHYLBENZ[A]ANTHRACENE; HORMONE; TRANSFORMING GROWTH FACTOR BETA; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER SURVIVAL; CONTROLLED STUDY; ISOGRAFT; MAMMARY GLAND; MOUSE; MOUSE STRAIN; MYOEPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STAINING; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; TUMOR GROWTH; WILD TYPE;

ANIMALIA; MUS MUSCULUS;

EID: 33644935417     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1111/j.1432-0436.2006.00056.x     Document Type: Article

References (57)

1. Akhurst RJ. 2002 TGF-beta antagonists why suppress a tumor suppressor? J Clin Invest 109 1533 1536
2. Bandyopadhyay A. Zhu Y. Cibull ML. Bao L. Chen C. Sun L. 1999 A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells Cancer Res 59 5041 5046
3. Barcellos-Hoff MH. Ewan KB. 2000 Transforming growth factor-beta and breast cancer mammary gland development Breast Cancer Res 2 92 99
4. Bhowmick NA. Chytil A. Plieth D. Gorska AE. Dumont N. Shappell S. Washington MK. Neilson EG. Moses HL. 2004 TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia Science 303 848 851
5. Boecker W. Buerger H. 2003 Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium a new progenitor (adult stem) cell concept Cell Prolif 36 Suppl 1 73 84
6. Bottinger EP. Jakubczak JL. Haines DC. Bagnall K. Wakefield LM. 1997 Transgenic mice overexpressing a dominant-negative mutant type II TGF-β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz- [a]-anthracene Cancer Res 57 5564 5570
7. Cardiff RD. Anver MR. Gusterson BA. Hennighausen L. Jensen RA. Merino MJ. Rehm S. Russo J. Tavassoli FA. Wakefield LM. Green J. 2000a The mammary pathology of genetically engineered mice the consensus report and recommendations from the Annapolis meeting Oncogene 19 968 988
8. Cardiff RD. Gumerlock PH. Soong MM. Dandekar S. Barry PA. Young LJ. Meyers FJ. 1988 c-H-ras-1 expression in 7,12-dimethyl benzanthracene-induced Balb/c mouse mammary hyperplasias and their tumors Oncogene 3 205 213
9. Cardiff RD. Wagner U. Hennighausen L. 2000b Mammary cancer in humans and mice a tutorial for comparative pathology. The CD-ROM J Mammary Gland Biol Neoplasia 5 243 244
10. Cheng N. Bhowmick NA. Chytil A. Gorska AE. Brown KA. Muraoka R. Arteaga CL. Neilson EG. Hayward SW. Moses HL. 2005 Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-a, MSP-, and HGF-mediated signaling networks Oncogene 24 5053 5068
11. Crowley M. Bowtell DD. Serra R. 2005 TGF-β, c-Cbl, and PDGFRa in the mouse mammary stroma Develop Biol 279 58 72
12. Dandekar S. Sukumar S. Zarbl H. Young LJT. Cardiff RD. 1986 Specific activation of the cellular Harvey-ras oncogene in dimethylbenzanthracene-induced mouse mammary tumors Mol Cell Biol 6 4104 4108
13. Daniel CW. Robinson S. Silberstein GB. 2001 The transforming growth factors beta in development and functional differentiation of the mouse mammary gland Adv Exp Med Biol 501 61 70
14. Derynck R. Akhurst RJ. Balmain A. 2001 TGF-beta signaling in tumor suppression and cancer progression Nat Genet 29 117 129
15. Deugnier MA. Teuliere J. Faraldo MM. Thiery JP. Glukhova MA. 2002 The importance of being a myoepithelial cell Breast Cancer Res 4 224 230
16. Dontu G. Al-Hajj M. Abdallah WM. Clarke MF. Wicha MS. 2003 Stem cells in normal breast development and breast cancer Cell Prolif 36 Suppl 1 59 72
17. Draper N. Smith H. 1998 Applied regression analysis Wiley New York
18. Dumont N. Arteaga CL. 2003 Targeting the TGF beta signaling network in human neoplasia Cancer Cell 3 531 536
19. Erickson AC. Barcellos-Hoff MH. 2003 The not-so innocent bystander the microenvironment as a therapeutic target in cancer Expert Opin Ther Targets 7 71 88
20. Ewan KB. Shyamala G. Ravani SA. Tang Y. Akhurst R. Wakefield L. Barcellos-Hoff MH. 2002 Latent TGF-beta activation in mammary gland Am J Pathol 160 2081 2093
21. Freedman LS. 1982 Tables of the number of patients required in clinical trials using the logrank test Stat Med 1 121 129
22. Gobbi H. Arteaga CL. Jensen RA. Simpson JF. Dupont WD. Olson SJ. Schuyler PA. Plummer WD. Jr. Page DL. 2000 Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas [see comments] Histopathology 36 168 177
23. Gobbi H. Dupont WD. Simpson JF. Plummer WD. Jr. Schuyler PA. Olson SJ. Arteaga CL. Page DL. 1999 Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia J Natl Cancer Inst 91 2096 2101
24. Gorska AE. Jensen RA. Shyr Y. Aakre ME. Bhowmick NA. Moses HL. 2003 Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation Am J Pathol 163 1539 1549
25. Gorska AE. Joseph H. Derynck R. Moses HL. Serra R. 1998 Dominant-negative interference of the transforming growth factor beta type II receptor in mammary epithelium results in alveolar hyperplasia and differentiation in virgin mice CGD 9 229 238
26. Guzman RC. Osborn RC. Swanson SM. Sakthivel R. Hwang SI. Miyamoto S. Nandi S. 1992 Incidence of c-Ki-ras activation in N-methyl-N-nitrosourea-induced mammary carcinomas in pituitary-isografted mice Cancer Res 52 5732 5737
27. Huseby RA. Soares MJ. Talamantes F. 1985 Ectopic pituitary grafts in mice hormone levels, effects on fertility, and the development of adenomyosis uteri, prolactinomas, and mammary carcinomas Endocrinology 116 1440 1448
28. Joseph H. Gorska AE. Sohn P. Moses HL. Serra R. 1999 Overexpression of a kinase-deficient TGF-ß type II receptor in mouse mammary stroma results in increased epithelial branching Mol Biol Cell 10 1221 1234
29. Kumar R. Sukumar S. Barbacid M. 1990 Activation of ras oncogenes preceding the onset of neoplasia Science 248 1101 1104
30. Li W. Qiao W. Chen L. Xu X. Yang X. Li D. Li C. Brodie SG. Meguid MM. Hennighausen L. Deng CX. 2003a Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice Development 130 6143 6153
31. Li Y. Welm B. Podsypanina K. Huang S. Chamorro M. Zhang X. Rowlands T. Egeblad M. Cowin P. Werb Z. Tan LK. Rosen JM. Varmus HE. 2003b Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells Proc Natl Acad Sci USA 100 15853 15858
32. Lifsted T. Le Voyer T. Williams M. Muller W. Klein-Szanto A. Buetow KH. Hunter KW. 1998 Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression Int J Cancer 77 640 644
33. Lin EY. Gouon-Evans V. Nguyen AV. Pollard JW. 2002 The macrophage growth factor CSF-1 in mammary gland development and tumor progression J Mammary Gland Biol Neoplasia 7 147 62
34. Lydon JP. Ge G. Kittrell FS. Medina D. O'Malley BW. 1999 Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function Cancer Res 59 4276 4284
35. Maffini MV. Soto AM. Calabro JM. Ucci AA. Sonnenschein C. 2004 The stroma as a crucial target in rat mammary gland carcinogenesis J Cell Sci 117 1495 1502
36. Massague J. 1998 TGF-ß signal transduction Ann Rev Biochem 67 753 791
37. Massague J. Blain SW. Lo RS. 2000 TGFbeta signaling in growth control, cancer, and heritable disorders Cell 103 295 309
38. Medina D. 1974a Mammary tumorigenesis in chemical carcinogen-treated mice. I. Incidence in BALB-c and C57BL mice J Natl Cancer Inst 53 213 221
39. Medina D. 1974b Mammary tumorigenesis in chemical carcinogen-treated mice. II. Dependence on hormone stimulation for tumorigenesis J Natl Cancer Inst 53 223 226
40. Miller R. 1981 Survival analysis Wiley New York
41. Muraoka RS. Dumont N. Ritter CA. Dugger TC. Brantley DM. Chen J. Easterly E. Roebuck LR. Ryan S. Gotwals PJ. Koteliansky V. Arteaga CL. 2002 Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases J Clin Invest 109 1551 1559
42. Pelton RW. Dickinson ME. Moses HL. Hogan BLM. 1990 In situ hybridization analysis of TGF-β3 RNA expression during mouse development comparative studies with TGF-β1 and -β2 Development 110 600 620
43. Petersen OW. Gudjonsson T. Villadsen R. Bissell MJ. Ronnov-Jessen L. 2003 Epithelial progenitor cell lines as models of normal breast morphogenesis and neoplasia Cell Prolif 36 Suppl 1 33 44
44. Pierce DF. Jr. Gorska AE. Chytil A. Meise KS. Page DL. Coffey RJ. Jr. Moses HL. 1995 Mammary tumor suppression by transforming growth factor β1 transgene expression Proc Natl Acad Sci USA 92 4254 4258
45. Rehm S. 1990 Chemically induced mammary gland adenomyoepitheliomas and myoepithelial carcinomas of mice. immunohistochemical and ultrastructural features Am J Pathol 136 575 584
46. Roberts AB. Sporn MB. 1990 The transforming growth factor-βs In Sporn MB. Roberts AB. (eds.). Peptide growth factors and their receptors Springer-Verlag Heidelberg pp. 419 472
47. Roberts AB. Wakefield LM. 2003 The two faces of transforming growth factor beta in carcinogenesis Proc Natl Acad Sci USA 100 8621 8623
48. Rosen PP. 1997a Myoepithelial neoplasms In Breast pathology Lippincott-Raven Philadelphia pp. 105 122
49. Rosner A. Miyoshi K. Landesman-Bollag E. Xu X. Seldin DC. Moser AR. MacLeod CL. Shyamala G. Gillgrass AE. Cardiff RD. 2002 Pathway pathology histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors Am J Pathol 161 1087 1097
50. Rosner B. 2000 Fundamentals of biostatistics 5th edn Duxbury Pacific Grove, CA
51. Russo J. Russo IH. 1996 Experimentally induced mammary tumors in rats Breasst Cancer Res. Treat. 39 7 20
52. Sadlonova A. Novak Z. Johnson M. Bowe D. Goult S. Page G. Thottassery J. Welch D. Frost A. 2005 Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture Breast Cancer Res 7 R46 59
53. Serra R. Crowley M. 2003 TGF-β in mammary gland development and breast cancer Breast Disease 18 61 73
54. Serra R. Moses HL. 1996 Tumor suppressor genes in the TGF-β signaling pathway? Nat Med 2 390 391
55. Siegel PM. Shu W. Cardiff RD. Muller WJ. Massague J. 2003 Transforming growth factor {beta} signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis Proc Natl Acad Sci USA 100 8430 8435
56. Wakefield LM. Yang YA. Dukhanina O. 2000 Transforming growth factor-beta and breast cancer lessons learned from genetically altered mouse models Breast Cancer Res 2 100 106
57. Yang YA. Dukhanina O. Tang B. Mamura M. Letterio JJ. MacGregor J. Patel SC. Khozin S. Liu ZY. Green J. Anver MR. Merlino G. Wakefield LM. 2002 Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects J Clin Invest 109 1607 1615